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Abstract
Current influenza vaccines fail to induce protection against antigenically distinct virus strains. Accordingly, there is a need
for the development of cross-protective vaccines. Previously, we and others have shown that vaccination with whole
inactivated virus (WIV) induces cross-protective cellular immunity in mice. To probe the mechanistic basis for this finding,
we investigated the role of TLR7, a receptor for single-stranded RNA, in induction of cross-protection. Vaccination of TLR72/
2 mice with influenza WIV failed to protect against a lethal heterosubtypic challenge; in contrast, wild-type mice were fully
protected. The lack of protection in TLR72/2 mice was associated with high viral load and a relative paucity of influenza-
specific CD8+ cytotoxic T lymphocyte (CTL) responses. Dendritic cells (DCs) from TLR72/2 mice were unable to cross-
present WIV-derived antigen to influenza-specific CTLs in vitro. Similarly, TLR72/2 DCs failed to mature and become
activated in response to WIV, as determined by the assessment of surface marker expression and cytokine production.
Plasmacytoid DCs (pDCs) derived from wild-type mice responded directly to WIV while purified conventional DCs (cDCs) did
not respond to WIV in isolation, but were responsive in mixed pDC/cDC cultures. Depletion of pDCs prior to and during WIV
immunization resulted in reduced numbers of influenza-specific CTLs and impaired protection from heterosubtypic
challenge. Thus, TLR7 plays a critical role in the induction of cross-protective immunity upon vaccination with WIV. The
initial target cells for WIV appear to be pDCs which by direct or indirect mechanisms promote activation of robust CTL
responses against conserved influenza epitopes.
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Introduction
Influenza continues to represent a major global health burden
[1]. Although vaccination is the cornerstone of control, current
seasonal influenza vaccines offer only narrow protection. These
vaccines induce neutralizing antibodies primarily against hemag-
glutinin (HA) and neuraminidase (NA), the highly variable surface
glycoproteins of the virus [2,3]. Thus, vaccine-induced immune
responses are largely strain-specific and fail to protect against
antigenically-drifted or newly-emerging shifted viruses with
pandemic potential. These limitations underscore the need for
novel, cross-protective influenza vaccines [4,5].
Previously, we and others have shown that vaccination with
whole inactivated virus (WIV) induces cross-protection against
lethal heterosubtypic infection in mice, in contrast to subunit and
split virion vaccines, which did not show any cross-protective
capacity [6,7]. This WIV-induced cross-protective effect is
mediated principally by CD8+ cytotoxic T lymphocytes (CTLs).
Indeed, the extent of protection has been shown to correlate with
the number of influenza nucleoprotein (NP)-specific CTLs induced
by vaccination. Furthermore, depletion of CD8+ cells results in
loss of protection [6,7]. Thus, WIV-induced cross-protection
against heterosubtypic influenza infection in mice depends on the
consequent CTL response, which operates to reduce viral load in
the lungs after lethal dose challenge.
Naive CTLs are primed by dendritic cells (DCs), which
present the respective peptide antigen in a major histocompat-
ibility complex (MHC) class I-restricted manner and provide
additional co-stimulation [8,9]. Antigens produced in the cytosol
of DCs, such as viral proteins in the case of infection, have
direct access to the MHC class I presentation pathway. Other
antigens, such as those present in WIV, can access this pathway
through a process known as cross-presentation [10,11]. Only
mature and activated DCs are licensed for successful cross-
presentation of exogenous antigens [11]. Accordingly, proper
activation of DCs is considered to be a key event in the
induction of specific CTL responses to non-replicative antigens
like WIV [12,13]. Previously, we showed that WIV activates
bone marrow-derived conventional (cDCs) and plasmacytoid
DCs (pDCs) and that activation of the latter is dependent on
engagement of Toll-like receptor 7 (TLR7) by the single-
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stranded (ss) viral RNA in WIV [14,15]. In the present study,
we investigated the role of TLR7 signaling in the induction by
WIV of CTL responses and cross-protective immunity against
lethal heterosubtypic challenge.
Strikingly, TLR7-deficient (TLR72/2) mice were not
protected from lethal H1N1 challenge by vaccination with
H5N1 WIV, whereas wild-type (wt) mice were fully protected.
The absence of cross-protection in vaccinated TLR72/2 mice
correlated with a lack of NP-specific CTLs. In vitro, bone
marrow-derived TLR72/2 DCs were incapable of presenting
WIV-derived antigens to primed NP-specific CTLs and failed to
undergo maturation and activation in response to WIV
exposure. Sorted bone marrow-derived plasmacytoid DCs
(pDCs), but not sorted conventional DCs (cDCs), from wt mice
responded directly to WIV stimulation by surface marker (MHC
class I, CD86, CD80, CD40) upregulation and cytokine (IFNa
and IL12) secretion. In mice depleted of pDCs during
immunization, CTL induction and protection against hetero-
subtypic challenge were impaired. Thus, TLR7 triggering is
essential for the successful induction of cross-protective cellular
immunity by WIV. The primary target cells for the vaccine are




All mouse experiments were performed in strict accordance
with Dutch legislation on animal experiments (‘‘Wet op de
dierproeven’’, 1977; modified in 1996 with implementation of the
European guidelines 86/609/EEG and ‘‘Dierproevenbesluit
1985’’) and approved by the Ethics Committee on Animal
Research of the University Medical Center Groningen (Permit
number: 5101B).
Virus Strains and Vaccines
Egg-derived A/PR/8/34 (H1N1) virus and egg-derived A/
New Caledonia/IVR 116 (H1N1) virus were kind gifts from
Solvay Biologicals (Weesp, The Netherlands); these viruses were
further amplified on eggs according to standard procedures. A/
NIBRG-14, a genetic reassortant of A/PR/8/34 and A/
Vietnam/1194/2004 (H5N1), was obtained from NIBSC
(Potters Bar, UK) and cultured on Madine-Darby Canine
Kidney (MDCK) cells. WIV vaccine was prepared by in-
activation of NIBRG-14 virus for 24 hr with 0.1% b–
propiolactone (BPL; Acros Organics, Geel, Belgium) at room
temperature, followed by dialysis for 24 hr against HNE buffer
(5 mM HEPES, 150 mM NaCl, 0.1 mM EDTA, pH 7.4).
Inactivation of the virus was tested by performing serial passages
on eggs, according to the protocol published in the European
Pharmacopeia [16]. Specifically, one vaccine dose containing
20 mg of total viral protein was injected into the allantoic cavity of
each of 20 fertilized eggs and eggs were incubated for 3 days at
33uC. Subsequently, 1 ml aliquots of allantoic fluid from each egg
were pooled, and 200 ml was inoculated into each new egg. This
passage was repeated once more. After the last passage, allantoic
fluid was harvested and the absence of replicative virus was
demonstrated by a hemagglutination test, as described elsewhere
[17].
Mice
Female C57Bl/6 and TLR72/2 mice, 8–10 weeks old, were
used in immunization and challenge studies. C57Bl/6 mice were
vendor sourced (Harlan, The Netherlands) and TLR72/2 mice
(a kind gift from S. Akira and C. Reis e Sousa) were bred at the
animal facility of the University Medical Center Groningen
(Groningen, The Netherlands). All mice were kept under SPF
conditions in conventional cages and had access to food and water
ad libitum.
All experimental handeling of mice, such as vaccination, blood
sampling, challenge and euthanasia, were performed under
isoflurane anesthesia. Animals were euthanized at the indicated
time or when weight loss exceeded 20%. Euthanasia was
performed by heart puncture under isoflurane anesthesia.
Vaccination and Heterosubtypic Challenge
C57Bl/6 and TRL72/2 mice (5–6 per experimental group)
were vaccinated twice (days 0 and 21) with 20 mg of NIBRG-14
(H5N1) WIV administered subcutaneously (s.c.) or similarly
mock-vaccinated with HNE buffer as described previously [6].
One week after the booster immunization, mice were anesthe-
tized and inoculated intranasally with 100 PFU of PR8 (H1N1)
in 40 ml saline. After the challenge, mice were monitored daily
for body weight change. Body weight loss of more than 20% was
considered an indication for euthanasia. On day 6 post-
challenge, 6 mice from each group were euthanized, and lungs
and BAL were collected for analysis of virus titers, tetramer
staining and granzyme B measurements. Mice that did not lose
more than 20% of their body weight were euthanized on day 14
post-challenge for analysis of virus titers and immunological
parameters.
Protocols for virus titration in the lung tissue and tetramer
staining of lung-derived lymphocytes are described elsewhere [6].
Granzyme B content in BAL was measured by ELISA (R&D
Systems, Abingdon, UK) according to the manufacturer’s pro-
tocol.
In vivo Cytotoxicity Assay
C57Bl/6 and TLR72/2 mice were vaccinated twice (days
0 and 21) with either 25 mg of NIBRG-14 WIV (s.c.) or 400 HAU
of A/New Caledonia live virus (i.p.); HNE mock-vaccinated (s.c.)
mice served as negative controls. On days 7 and 8 after the booster
immunization, an in vivo cytotoxicity assay was performed as
described previously [6].
In vitro Reactivation of Influenza-specific CTLs and
Tetramer Staining
Naive C57Bl/6 mice were primed by intraperitoneal injection
of 400 HAU of A/New Caledonia live virus. Three weeks later,
spleens were dissected and collected on ice in complete Iscove’s
modified Dulbecco’s medium (IMDM; Invitrogen, Breda, The
Netherlands). Splenocytes were isolated by homogenizing
spleens through cell strainers (BD Biosciences) and resuspended
in medium. After 10 min centrifugation (3506g) at 4uC,
erythrocytes were removed by lysis using ACK buffer
(0.15 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4).
Subsequently, 107 splenocytes were cocultured with 106 wt or
TLR72/2 DCs previously pulsed with 5 mg/ml of WIV. As
a control, 106 TLR72/2 DCs were pulsed with 5 mg/ml WIV
supplemented with 10 mg/ml ODN1826 CpG (InvivoGen,
Toulouse, France). Cocultures were performed in T25 flasks
in complete IMDM supplemented with 10 U/ml IL2 (Pepro-
Tech, London, UK). After 7 days, cells were centrifuged,
resuspended in PBS supplemented with 1% bovine serum
albumin (BSA) and 5 mM EDTA, and stained for 45 min at
4uC with anti-mouse CD8a a-allophycocyanin (ImmunoSource,
Halle-Zoersel, Belgium) and influenza NP366–374 tetramer-
TLR7-Dependent Cross-Protection against Influenza
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phycoerythrin (PE). Tetramers were produced by conjugation of
soluble biotinylated NP366–374/H-2Db monomeric protein at
a 4:1 molar ratio with PE-conjugated streptavidin as described
elsewhere [18]. Dead cells were excluded from flow cytometric
analyses using 7AAD (ImmunoSource).
Culture, Maturation and Activation of DCs
DCs were generated from murine bone marrow isolated from
tibia and femur of C57Bl/6 (wt DCs) and TLR72/2 (TLR72/2
DCs) mice, and cultured for 8 days in IMDM supplemented with
10% heat-inactivated fetal bovine serum (FBS), 1% antibiotics,
0.1% b-mercaptoethanol (Invitrogen) and 200 ng/ml Flt3L (R&D
Systems).
Upregulation of surface marker expression was measured by
flow cytometry after pulsing DCs with either WIV (5 mg/ml), CpG
(10 mg/ml) or culture medium. A total of 36106 DCs were
incubated at 16106 cells/ml with each stimulating agent at 37uC
in complete IMDM. One portion of 36106 wt DCs was incubated
for 3 hr with the TLR7 antagonist IRS661 (5 mg/ml; Eurogentec,
Maastricht, The Netherlands), then pulsed with WIV (5 mg/ml).
Cells were stained with directly conjugated anti-mouse mono-
clonal antibodies (ImmunoSource) specific for MHC class I,
CD86, CD80 and CD40 according to a standard protocol. Flow
cytometric analysis was conducted using a FACSCalibur (BD
Biosciences).
Production of IL12 was measured in cell culture supernatants by
ELISA (ImmunoSource) according to the manufacturer’s protocol.
Detection of IFNa was performed according to an ELISA protocol
published elsewhere [14].
pDC/cDC Sorting
After 8 days in culture, DCs were stained with anti-mouse
CD11b-PECy7, anti-mouse B220-eFluor450 and anti-mouse
CD11c-PE (ImmunoSource) and sorted using a FACSAria (BD
Biosciences) cell sorter to separate pDC and cDC populations.
pDCs were identified as B220+CD11c+CD11b2 cells and cDCs
were identified as B220-CD11c+CD11b+ cells [19]. After sorting,
cells were collected in FBS-coated FACS tubes at a final
concentration of 70% FBS.
pDC Depletion
pDC depletion was performed by administration of purified
pDC-depleting monoclonal antibody (clone 120G8) [20]. On 3
consecutive days (1 day pre-vaccination, day of vaccination and 1
day post-vaccination) mice were injected i.p. with 300 mg of the
depletion antibody. This pDC depletion procedure was repeated
once more during the booster vaccination (days 20–22). Control
mice received the same amount of isotype control antibody or
PBS. The efficacy of pDC depletion was determined in bone-
marrow derived cells 1 day after the last depletion dose was
administered. pDCs were identified using two different staining
strategies (CD11b2CD11c+PDCA-1+ and
CD11b2CD11c+B220+) followed by flow cytometric analysis.
Results of depletion are depicted in the figure S1.
Statistical Methods
Statistical differences between different treatment groups were
analyzed using the Mann-Whitney U-test with a confidence
interval of 95%. A value of p,0.05 was considered statistically
significant (depicted as an asterisk).
Results
Role of TLR7 Signaling in WIV-induced Heterosubtypic
Cross-protection
To investigate the role of TLR7 signaling in WIV-induced
heterosubtypic protection, we vaccinated wt and TLR72/2 mice
with two doses of WIV derived from A/H5N1 virus (NIBRG-14).
One week after the second immunization, mice were exposed to
a lethal challenge with A/H1N1 virus (PR8) and monitored for 14
days or euthanized when their body weight loss exceeded 20%. All
of the vaccinated wt mice survived the lethal heterosubtypic
challenge without significant weight loss. In contrast, all of the
vaccinated TLR72/2 mice, together with the mock-vaccinated
controls, had lost more than 20% of their body weight by day 9
post-challenge and were euthanized (Fig. 1A).
On day 6 post-challenge, we assessed virus clearance from the
lungs of the challenged mice. As expected, lung virus titers were
reduced by almost 3 logs in WIV-vaccinated wt mice compared to
mock-vaccinated mice. In contrast, viral titers in the lungs of
TLR72/2 mice vaccinated with WIV were high and similar to
those measured in the lungs of mock-vaccinated controls (Fig. 1B).
Thus, TLR7 is critically involved in WIV-induced control of
virus growth in the lungs and protection from lethal heterologous
virus challenge.
Role of TLR7 Signaling in WIV-mediated Induction of
Influenza-specific CTLs
Previously, we showed that WIV-induced cross-protection of
mice is mediated primarily by influenza-specific CTLs. Therefore,
we now investigated whether the observed lack of cross-protection
in TLR72/2 mice was due to an impaired CTL response in these
animals. Wt and TLR72/2 mice were immunized twice with
H5N1 WIV. Seven days after the second immunization, CTLs
specific for the NP366–374 epitope were quantified by peptide-
MHC class I tetramer staining. As depicted in Figure 2A,
tetramer-positive CD8+ cells were detected in the spleens of
WIV-immunized wt mice but not in the spleens of WIV-
immunized TLR72/2 mice. The mutant mice were not impaired
in terms of their ability to generate CTLs per se, as intraperitoneal
injection of live influenza virus resulted in similarly high numbers
of NP366–374 tetramer-positive cells in both wt and TLR72/2
mice (Fig. 2A). Live influenza virus has the capacity to activate
innate immune receptors such as RLRs (e.g. RIG-I), NLRs (e.g.
NLRP3) and TLR3, and thus does not necessarily require TLR7
to enable CTL activation [21–24].
In addition, we assessed the induction of influenza-specific CTL
activity by measuring the level of in vivo cytotoxicity after
immunization with WIV. To this end, we injected CFSE-labeled,
NP366–374 peptide-loaded target splenocytes from wt donor mice
into recipient wt and TLR72/2 mice immunized with H5N1
WIV. One day later, target cell survival was scored in the spleen.
Figure 2B depicts the cytotoxic activity of influenza-specific CTLs
against peptide-loaded target cells. Immunization of wt mice with
WIV induced high levels of cytotoxicity in these animals. In
contrast, lysis of target cells was not detected in TLR72/2 mice
after immunization with WIV. When CTLs were primed by
infection with live virus, both wt and TLR72/2 mice displayed
similar levels of cytotoxicity against peptide-loaded target cells.
Next, we assessed the induction of CTL activity in the lungs of
mice after vaccination and heterosubtypic challenge. To this end,
wt and TLR72/2 mice were vaccinated twice with H5N1 WIV
and, one week after the booster dose, exposed to a lethal
heterosubtypic challenge with H1N1 virus. Six days later, the mice
were sacrificed and local cytotoxic immune responses were
TLR7-Dependent Cross-Protection against Influenza
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evaluated in lung tissue and bronchoalveolar lavage (BAL) by
NP366–374 tetramer staining and granzyme B measurement,
respectively. Substantial numbers of tetramer-positive CD8+ cells
were detected in the lungs of wt mice vaccinated with WIV
(Fig. 3A). In contrast, very few tetramer-positive CD8+ cells were
detected in the lungs of WIV-vaccinated TLR72/2 mice,
numbers barely exceeding those observed in the lungs of mock-
vaccinated control mice. In parallel, granzyme B was absent in
BAL collected from the vaccinated TLR72/2 mice, while high
levels were detected in BAL from their vaccinated wt counterparts
(Fig. 3B).
Collectively, these data indicate that TLR7 activation is crucial
for the induction of influenza-specific CTL activity upon
vaccination with WIV.
Role of TLR7 Signaling in Cross-presentation of WIV-
derived Antigen
Originating from a non-replicative vaccine, WIV-derived
antigens must be presented to CD8+ T cells by professional
antigen-presenting cells (APCs), specifically DCs, by a process of
cross-presentation. To determine the role of TLR7 in cross-
presentation of WIV-derived antigens (e.g. epitopes derived
Figure 1. Heterosubtypic cross-protection induced by WIV depends on TLR7 activation. Wt and TLR72/2 mice were either vaccinated
twice (on days 0 and 21) subcutaneously (s.c.) with 20 mg of H5N1 WIV or similarly mock-vaccinated with HNE buffer. A lethal heterosubtypic
challenge with H1N1 virus was administered one week later. (A) After challenge, mice were monitored daily over a period of 14 days for body weight
change. Body weight loss of more than 20% was an indication for euthanasia (dashed line). (B) Virus titers in the lungs of wt (black bars) and TLR72/2
(white bars) mice were measured 6 days post-challenge. Bars represent mean6SEM of 3 mice per group. *p,0.05; Mann-Whitney U-test.
doi:10.1371/journal.pone.0063163.g001
Figure 2. Influenza-specific cytotoxicity in vivo depends on TLR7 activation. Wt (black bars) and TLR72/2 (white bars) mice received two
doses (on day 0 and 21) of WIV (25 mg; s.c.), replicative virus (400 HAU; i.p.) or HNE buffer (s.c.). One week later, mice were injected through the orbital
vein with a 1:1 mixture of NP- and OVA-pulsed target cells, differentially labeled with high and low concentrations of CFSE, respectively. NP366–374
tetramer-positive CD8+ T cells (A) and cytotoxicity expressed as % of killed target cells (B) were measured by tetramer staining and flow cytometric
analysis of splenocytes isolated from immunized mice 13 hours after target cell injection. Gating was based on the forward-side scatter pattern and
dead cells (7AAD+) were excluded. Finally, gates were set on CD8+tetramer+ cells. Results are representative of 3 independent experiments. Bars
represent mean6SEM of 5 mice per group. *p,0.05; Mann-Whitney U-test.
doi:10.1371/journal.pone.0063163.g002
TLR7-Dependent Cross-Protection against Influenza
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from NP), we investigated the capacity of WIV-pulsed bone
marrow-derived TLR72/2 DCs to induce in vitro restimulation
of influenza-specific CD8+ T cells. The degree of restimulation
was assessed by enumeration of NP366–374 tetramer-positive cells
by flow cytometry before and after in vitro coculture. Stimulation
of primed CD8+ T cells for 7 days with wt DCs exposed to
WIV induced massive expansion of the NP366–374 tetramer-
positive CD8+ T cell population (Fig. 4A & 4B). In contrast,
coculture of primed CD8+ T cells with TLR72/2 DCs pulsed
with WIV did not induce proliferation of NP366–374 tetramer-
positive CD8+ T cells (Fig. 4C). To demonstrate that the
absence of in vitro CTL restimulation by WIV-pulsed TLR72/
2 DCs was not an intrinsic defect of TLR72/2 cells, we
incubated these cells simultaneously with WIV and a TLR9
ligand (CpG oligodeoxynucleotides). As shown in Figure 4D,
CpG-mediated TLR9 activation could compensate for the
absence of TLR7 signaling, resulting in efficient expansion of
NP366–374 tetramer-positive CD8+ T cells. These data demon-
strate a crucial role for TLR7 in the cross-presentation of WIV-
derived antigens, specifically NP, by DCs.
Role of TLR7 Signaling in WIV-induced Maturation and
Activation of DCs
It is established that only DCs with a mature and activated
phenotype are capable of effective antigen presentation [11,25].
To investigate the role of TLR7 signaling in the induction of such
a phenotype, we compared the responses of wt and TLR72/2
bone marrow-derived DCs to stimulation with WIV. In addition,
we investigated WIV-induced maturation and activation of wt DCs
in which TLR7 signaling was blocked using a specific antagonist
(IRS661).
As depicted in Figure 5, wt DCs exhibited a marked upregula-
tion of surface maturation markers (MHC class I, CD86, CD80
and CD40) in response to stimulation with WIV. In contrast,
expression of these markers remained unchanged in parallel
experiments with TLR72/2 DCs. Consistent with this observa-
tion, inhibition of TLR7 completely abolished WIV-induced
surface marker upregulation in wt DCs. The absence of a response
in TLR72/2 DCs was not due to an intrinsic defect of these cells,
as activation with the TLR9 ligand CpG induced efficient
maturation of TLR72/2 DCs.
In addition, we measured IFNa and IL12 secretion to
determine the activation status of DCs (Fig. 6). Both cytokines
were secreted in a dose-dependent manner by wt DCs, but not
Figure 3. Local activation of influenza-specific CTLs in the lungs depends on TLR7 activation. (A) NP366–374 tetramer-positive CD8+ T cells
in the lungs of wt (black bars) and TLR72/2 (white bars) mice vaccinated with WIV were quantified on day 6 post-challenge. Gating strategy was as
described in the legend to Fig. 2 (B) Local production of granzyme B in the lungs of wt (black bars) and TLR72/2 (white bars) mice vaccinated with
WIV was measured on day 6 post-challenge by ELISA performed on BAL samples. Bars represent mean6SEM of 3 mice per group. *p,0.05; Mann-
Whitney U-test.
doi:10.1371/journal.pone.0063163.g003
Figure 4. In vitro restimulation of primed influenza-specific CD8+ T cells by DCs depends on TLR7 activation.Wtmice were primed with
400 HAU of live influenza A/New Caledonia virus (i.p.). NP366–374 tetramer-positive CD8+ T cells were quantified in the spleen 3 weeks later (A).
Splenocytes from primed mice were cocultured for 7 days with either murine bone marrow-derived wt DCs (B), TLR72/2 DCs pulsed with WIV (C), or
TLR72/2 DCs pulsed with WIV+CpG (D). Gates were set on viable cells based on the forward/side scatter profile and exclusion of 7AAD+ cells.
Frequencies of NP366–374 tetramer-positive CD8+ T cells are shown as a percentage of the total CD8+ T cell population. Results are representative of 4
independent experiments.
doi:10.1371/journal.pone.0063163.g004
TLR7-Dependent Cross-Protection against Influenza
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TLR72/2 DCs, after stimulation with WIV. Consistently,
blockade of TLR7 signaling in wt DCs completely inhibited the
induction of IFNa and IL12. TLR72/2 DCs were capable of
producing IFNa and IL12 when stimulated with CpG demon-
strating the general capacity to produce cytokines.
These results demonstrate that TLR7 signaling controls the
maturation and activation of DCs upon exposure to WIV.
Role of TLR7 in Activation and Maturation of
Plasmacytoid DCs (pDCs) and Conventional DCs (cDCs)
Next, we assessed the capacity of two major DC subpopulations,
pDCs and cDCs, to respond to WIV stimulation. Based on the
expression of characteristic surface markers, pDCs
(B220+CD11c+CD11b2) and cDCs (B220-CD11c+CD11b+)
from bone marrow cultures of both wt and TLR72/2 mice
Figure 5. WIV-induced maturation of DCs depends on TLR7 activation. Murine bone marrow-derived wt (black bars) and TLR72/2 (gray
bars) DCs were pulsed for 24 hr with WIV, WIV+IRS661, CpG or culture medium. Expression of the following maturation markers was measured by
flow cytometry: MHC class I (A), CD86 (B), CD80 (C) and CD40 (D). Gates were set on viable cells based on the forward/sideward scatter profile and
exclusion of 7AAD+ cells. Fold changes of mean fluorescence intensity are depicted. Results are representative of 3 independent experiments in each
of which 100000 cells were analyzed.
doi:10.1371/journal.pone.0063163.g005
Figure 6. WIV-induced production of IFN-a and IL-12 depends on TLR7 activation. Murine bone marrow-derived wt (black bars) and
TLR72/2 (gray bars) DCs were pulsed for 24 hr with different amounts of WIV (0.1, 1 and 10 mg), WIV+IRS661, CpG or culture medium. Secreted
concentrations of IFNa (A) and IL12 (B) were measured by ELISA. All measurements were performed in triplicate; bars represent mean6SEM. Results
are representative of 3 independent experiments. *p,0.05; Mann-Whitney U-test.
doi:10.1371/journal.pone.0063163.g006
TLR7-Dependent Cross-Protection against Influenza
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were sorted by flow cytometry; maturation and activation of these
separate cell populations was then assessed in response to WIV
stimulation. In sorted cultures, wt pDCs responded to WIV
stimulation by upregulation of surface maturation markers (Fig. 7,
left panels). In contrast, sorted cDCs were largely unresponsive to
WIV (Fig. 7, middle panels). Similarly, wt pDCs were activated by
WIV to secrete IFNa and IL12; no cytokine secretion was
observed in parallel experiments with wt cDCs (Fig. 8). In unsorted
cultures, a degree of maturation and activation was observed in
both pDCs and cDCs as indicated by a general shift of the cell
populations to higher fluorescence intensities, most pronounced
for MHC-I and CD80 (Fig. 7, right panels). As expected, surface
maturation marker upregulation and cytokine secretion were not
observed in either sorted or unsorted cultures of TLR72/2 DCs
(data not shown).
These results demonstrate that pDCs, but not cDCs, are
activated directly in response to WIV stimulation and acquire
a mature phenotype, in a TLR7-dependent manner. In contrast,
cDC maturation is induced only indirectly, most probably in
response to cytokines (e.g. IFNa) released by activated pDCs.
Role of pDCs in CTL Induction upon Immunization with
WIV in vivo
In order to obtain further insight into the role of pDCs in CTL
induction by WIV in vivo, we depleted mice from pDCs by
administering the pDC-specific antibody 120G8 prior to and
during immunization of mice. This treatment reduced the number
of pDCs (defined as PDCA-1+CD11c+CD11b2 or as
B220+CD11c+CD11b2) in bone marrow by a factor of 2–2.5
(Fig. S1). The level of depletion in spleen, assumed to be similar to
or even higher than in bone marrow, could not be determined due
to the notoriously low numbers of pDCs in spleen and blood of
C57Bl/6 mice [26].
Figure 7. WIV induces maturation of pDCs but not cDCs. Bone marrow-derived pDCs (B220+CD11c+CD11b2), cDCs (B220-CD11c+CD11b+)
and unsorted DCs were pulsed for 24 hr with WIV (gray histogram) or culture medium (white histogram). Upregulation of surface maturation marker
expression was measured by flow cytometry. Gates were set on viable cells based on the forward/side scatter profile and exclusion of 7AAD+ cells.
Numbers above each histogram represent the mean fluorescence intensity measured in medium-stimulated and WIV-stimulated DCs, respectively.
Results are representative of 3 independent experiments.
doi:10.1371/journal.pone.0063163.g007
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Mice which received pDC-depleting antibody developed
significantly lower numbers of NP-specific CD8+ T cells in
response to immunization with H5N1 WIV than non-treated mice
or mice which received an isotype control antibody instead of
120G8 (Fig. 9). When challenged with a lethal dose of H1N1 virus,
pDC-depleted mice showed significant weight loss despite the
immunization and two of the five mice had to be euthanized since
they lost more than 20% of body weight (Fig. 10A). In contrast,
non-treated mice or mice treated with a control antibody prior to
and during WIV immunization did not lose weight. As expected,
loss of weight was severe and rapid in non-immunized mice and
reached 20% in all animals by day 6–8. The observed weight loss
correlated with lung virus titers: pDC-depleted immunized mice
demonstrated a significantly higher viral load in the lungs than
non-depleted immunized mice (Fig. 10B). Yet, as compared to
non-immunized control mice virus titers in immunized pDC-
depleted mice were significantly reduced though to a moderateex-
tent.
Taken together these results indicate that pDCs play a crucial
role in the induction of CTLs by immunization with WIV in vivo.
Discussion
Here, we describe the role of the innate pattern recognition
receptor TLR7 in WIV-mediated induction of CTL responses and
heterosubtypic cross-protection against influenza infection. In
contrast to wt mice, TLR72/2 mice could not be protected from
heterosubtypic virus challenge by immunization with WIV,
indicating that TLR7 signaling plays a critical role in WIV-
induced cross-protective immunity. The lack of protection in
TLR72/2 mice was associated with the absence of specific WIV-
induced CTL responses, which was linked to impaired cross-
presentation of WIV-derived antigens by TLR72/2 DCs.
Consistently, TLR72/2 DCs were unresponsive to WIV. In
contrast, WIV induced the maturation and activation of wt DCs;
pDCs responded directly while cDCs responded in an indirect
way. pDCs also played a critical role in the induction of WIV-
induced CTL responses in vivo. These results suggest that
activation of TLR7 by WIV, particularly in pDCs, is crucial for
effective priming of influenza-specific CTLs and, consequently, for
the heterosubtypic cross-protection observed with this vaccine.
To our knowledge, the present study is the first to show that
TLR7 signaling plays an essential role in CTL priming by
immunization with WIV, and thus in the generation of
heterosubtypic immunity. Other authors have addressed the role
of TLR7 signaling in influenza WIV-induced homosubtypic
protection. For example, Koyama et al. observed decreased
survival in TLR72/2 mice compared to wt mice after
immunization with WIV derived from A/New Caledonia/20/99
(an H1N1 variant circulating in the last decade) and challenge
with A/PR/8/34 (an early H1N1 virus) [27,28]. This lack of
protection against a homosubtypic virus in WIV-immunized
TLR72/2 mice was explained by hampered antibody responses.
Other immune mechanisms were not investigated in these studies.
Extending the study of Koyama et al., we demonstrate here that
the lack of protection against heterosubtypic infection in WIV-
immunized TLR72/2 mice is closely correlated with hampered
cellular immune responses, in particular an almost complete
absence of influenza-specific CTLs.
Our study shows that, in the absence of TLR7 signaling, CTL
induction by WIV is largely abolished. In contrast, live influenza
Figure 8. WIV induces cytokine production in pDCs but not cDCs. Bone marrow-derived pDCs (B220+CD11c+CD11b2), cDCs (B220-
CD11c+CD11b+) and unsorted DCs were pulsed for 24 hr with WIV or culture medium. Secreted concentrations of IFNa (A) and IL12 (B) were
measured by ELISA. Bars represent mean6SEM of triplicates corrected for the medium control. Results are representative of 3 independent
experiments.
doi:10.1371/journal.pone.0063163.g008
Figure 9. pDCs play a role in in vivo induction of CTLs by WIV.
Mice were injected on day 0,1, and 2 with the pDC-depleting antibody
120G8 (pDC Ab), a non-specific isotype control (ctrl Ab) or left
untreated. On day 1 they were immunized s.c. with 20 mg of H5N1
WIV or mock-vaccinated with HNE buffer. The procedure of pDC
depletion and immunization was repeated on days 20–22. One week
later the level of NP-specific CD8+ T cells in peripheral blood was
evaluated by tetramer staining. Gating was based on the forward-side
scatter pattern and dead cells (7AAD+) were excluded. Finally, gates
were put on CD8+tetramer+ cells. Bars represent mean6SEM of 5 mice
per group. *p,0.05, **p,0.01; Mann-Whitney U-test.
doi:10.1371/journal.pone.0063163.g009
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virus was capable of inducing a strong antigen-specific CTL
response even in TLR72/2 mice, consistent with previous
observations (27). It is known that live virus can activate innate
receptors other than TLR7, such as RIG-I, which could result in
DC activation and, consequently, the induction of specific CTL
responses [27,28]. Indeed, recent evidence suggests that RIG-I
activation requires live virus replication in the cell [23,29]. This
finding explains the absence of RIG-I activation by non-replicative
WIV and, by extension, the strict TLR7-dependence of WIV-
induced CTL responses.
The natural ligand of TLR7 is single stranded (ss) RNA; viral
ssRNA is an intrinsic component of WIV, but not of other
influenza vaccines [6,15,30,31]. Our current study therefore
identifies viral ssRNA as the key component of WIV, not only
for the induction of superior humoral immune responses
dominated by the Th1-related antibody subtype IgG2a/c as
described earlier, but also for the induction of cellular immune
responses with cross-protective potential [15].
The observation that DCs cannot cross-present WIV-derived
antigens (e.g. NP-derived epitopes) in the absence of TLR7
signaling is a key mechanistic finding. Successful cross-presenta-
tion of exogenous antigens necessitates that DCs acquire a mature
and activated phenotype, characterized by upregulated expression
of MHC class I and costimulatory surface markers, and by the
production of specific cytokines. Immature DCs, as well as DCs
that have already matured before target antigen encounter, fail to
induce CTL activation [25,32]. One way by which DCs can
acquire a mature phenotype is through direct recognition of
pathogen-associated molecular patterns (PAMPs) by innate pattern
recognition receptors (PRRs) [23,33,34]. As mentioned above,
viral ssRNA is an integral component of WIV and, as a natural
ligand for TLR7, a potent activator of DC maturation [30]. In the
present study, we show that stimulation of DCs with WIV induced
maturation and activation in a strictly TLR7-dependent fashion.
This explains the complete failure of TLR72/2 DCs to cross-
present WIV-derived antigens.
Notably, WIV induced maturation and activation of isolated
pDCs; this was not apparent for cDCs in isolation. However, in
mixed cultures, cDCs also acquired a more mature phenotype,
likely in response to cytokines produced by activated pDCs (Fig. 7).
pDCs were also important for CTL induction upon WIV
immunization in vivo, as indicated by reduced numbers of CTLs
and impaired protection in mice immunized after depletion from
pDCs (Figs. 9, 10). It has to be mentioned that virus titers in pDC-
depleted mice were lower than in mock-immunized control mice
and these mice were partially protected from severe weight loss.
This could be either due to the residual pDCs (since depletion was
about 70 but not 100%). Alternatively, it might point to the fact
that other DC populations also participate or can take over in
absence of sufficient pDCs. Whether pDCs or cDCs are the
primary cell population cross-presenting WIV-derived antigens
in vivo remains unclear. Generally, CD8a+ lymphoid-organ-
resident cDCs are considered to be the major cell population in
mice capable of cross-presentation, followed by migratory
CD103+ DCs and inflammatory DCs [35–37]. pDCs are
generally considered to be poor APCs but are probably capable
of cross-presenting exogenous antigen and priming naive CD8+ T
cells when activated with the help of TLR ligands [37–40]. Kratky
et al. demonstrated that direct activation of the APC, e.g. via
TLRs, is required for successful induction of CTL responses [41].
This would point to pDCs as the most likely cross-presenting cell
population since these cells, in contrast to cDCs, could be activated
directly by WIV. However, the Kratky study was performed
in vitro in the absence of T helper cells capable of activating DCs
Figure 10. pDCs are important for WIV-afforded protection against heterologous challenge.Mice were depleted of pDCs and immunized
as described in the legend to Fig. 9. One week later they received a lethal heterosubtypic challenge with H1N1 virus. (A) Weight was monitored daily
for a period of 14 days. Weight loss of 15% (dashed line) was considered severe and weight loss of 20% (solid line) was an indication for euthanasia.
Individual mice are depicted. (B) 5 mice per treatment group were sacrificed on day 6 after challenge and lung virus titers were determined. Bars
represent mean6SEM. *p,0.05, **p,0.01; Mann-Whitney U-test.
doi:10.1371/journal.pone.0063163.g010
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through CD40 ligation, and is therefore of limited predictive value
for the situation in vivo. Taken together the available evidence
suggests that the ssRNA component of WIV directly activates
pDCs through TLR7. Thereby the pDCs are either themselves
licensed for cross-presentation of WIV-derived antigens or they
are activated to produce factors that license cDCs for doing so.
After activation by WIV, pDCs produce substantial amounts of
IFNaand IL12, both previously described to be essential for cross-
priming [42]. Type I IFNs, like IFNaenhance DC recruitment to
draining lymph nodes, prevent early antigen degradation and
promote routing of antigen to proper processing compartments
[42–44]. IL12, though not affecting the process of cross-pre-
sentation in DCs, is an important factor in functional maturation
of CTLs activated by cross-presenting DCs [42].
Thus, in addition to a possible direct role in cross-presentation,
pDCs likely contribute to influenza-specific CTL induction in
response to WIV via secretion of type I IFN and IL12, both known
to be intricately involved in CTL activation. Also in the context of
induction of antibody responses, and particular the Th1 domi-
nance of these responses, pDC-derived cytokines, e.g. type I IFN,
were shown to be crucially involved [15,28].
Our finding that TLR7 activation is critical for the induction of
influenza-specific CTL responses by WIV illustrates how a TLR
ligand, in this case ssRNA as an intrinsic component of the vaccine
itself, can act as an adjuvant. There are other examples of how the
CTL-inducing capacity of protein-based vaccines can be dramat-
ically improved by the introduction of TLR ligands. Jelenik et al.
showed that dsDNA (TLR3 ligand) facilitates CTL induction by
a NP-based experimental influenza vaccine [45]. Furthermore,
Wagner et al. demonstrated that the capacity of split vaccine to
induce protective responses mediated by CTLs could be improved
by supplementation with CpG (TLR9 ligand) [46]. Interestingly,
in contrast to these vaccines, influenza WIV already contains
ssRNA as an integral ‘‘built-in’’ adjuvant.
In conclusion, the results of the current study show that in mice
TLR7 signaling plays a crucial role in the induction of cross-
protective CTLs by vaccination with WIV. Activation of the
innate receptor underlies the capacity of this classic influenza
vaccine to provide protection against infection with heterosubtypic
influenza viruses. Viral ssRNA, an integral component of WIV, is
a natural ligand of TLR7 in mice and of TLR8 in humans and
represents a potent intrinsic adjuvant in this vaccine formulation.
Plasmacytoid DCs are the primary target cells for WIV and
probably contribute in multiple ways to the induction of cross-
protective cellular immunity. These insights provide a lead for the
further improvement of WIV-based vaccines as well as for the
development of other CTL-inducing vaccines.
Supporting Information
Figure S1 To verify successful depletion of pDCs bone
marrow was isolated from the femur of mice one day
after the administration of the last dose of buffer,
control antibody or the pDC-depleting antibody 120G8.
Cells were stained with antibodies specific for CD11b, CD11c and
B220 or PDCA-1. Cells were analyzed by flow cytometry. Gates
were set on viable cells based on the forward/side scatter profile
and exclusion of 7AAD+ cells. Next gate was set on CD11b2 cells
and pDCs were identified as CD11c+PDCA1+ or CD11c+B220+.
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